ARON 3D_Transparent

Renal Cell Carcinoma

MvtEc 1dQ1yGiYkyTNFLwQ

Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study. 

Santoni M, et al.
Target Oncol.
2023
1733740143737

Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group? 

Santoni M, et al.
Eur Urol Oncol.
2024
DBuV105KSlW5ffDBdIDZ0A

Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations

Porta C, et al.
Minerva Urol Nephrol.
2023
1733680902269

Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 Study

Monteiro FSM, et al.
Clin Genitourin Cancer.
2024
Fc8 3lWCRLqx7XOiJKnILg

Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study

Massari F, et al.
Eur Urol Oncol.
2024
Progetto senza titolo

Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study)

Fiala O, et al.
Target Oncol.
2024

Do you want to join us ?

Join us today
ARON 3D_Transparent
Youtube Linkedin

Coordinated and designed by Atteggiamento Digitale .

Legal and Privacy.